SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-134758
Filing Date
2024-05-09
Accepted
2024-05-09 07:17:01
Documents
16
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d834416d8k.htm   iXBRL 8-K 24127
2 EX-99.1 d834416dex991.htm EX-99.1 166150
6 GRAPHIC g834416sp1a.jpg GRAPHIC 8769
7 GRAPHIC g834416sp4.jpg GRAPHIC 14214
  Complete submission text file 0001193125-24-134758.txt   352851

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20240509.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20240509_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20240509_pre.xml EX-101.PRE 10815
20 EXTRACTED XBRL INSTANCE DOCUMENT d834416d8k_htm.xml XML 3727
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 24928550
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)